AIM: Metabolic profiling was performed on plasma samples obtained prior to and during @entity1161 ( @entity1161 ) for locally advanced @entity2 to identify metabolites predictive of @entity1161 -induced @entity2910 . @entity1 AND METHODS: @entity1 received @entity900 / @entity2879 with @entity1161 as part of a prospective dose-escalation study (n=24). Plasma samples were collected at baseline, weeks 2 and 5 during @entity1161 , and 6 weeks post- @entity1161 . Metabolites were measured by ultrahigh-performance liquid chromatography-tandem mass spectroscopy at each time-point. Metabolite concentrations were compared between @entity1 developing grade 0-1 and those with grade 2 or more @entity2910 . RESULTS: At baseline, 23 metabolites differed significantly (p<0.05) between @entity1 with grade 0-1 @entity2910 and those with grade 2 or @entity2910 . Sixty-seven metabolites were different at week 2. None reached statistical significance (q<0.05) after corrections for multiple comparisons. On random forest modeling, the predictive accuracy of the metabolite data was 33% at baseline and 50% at 2 weeks. CONCLUSION: No individual metabolite or group of metabolites was predictive of acute @entity1161 -induced @entity2910 .

Plasma Metabolites and Risk of Radiation-induced XXXX : A Secondary Analysis from a Prospective Study.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'PATIENTS'] @entity1161 :: ('MESH:D011832', 'Disease') :: ['radiation therapy', 'RT'] @entity2910 :: ('MESH:D004941', 'Disease') :: ['esophagitis'] @entity2 :: ('MESH:D008175', 'Disease') :: ['lung cancer'] @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin'] @entity2879 :: ('MESH:D005047', 'Chemical') :: ['etoposide']
@entity2910 :: (MESH:D004941,Disease) :: ['Esophagitis']
